Recent studies have shown that NSCLC patients with SMARCA4 mutations (especially homozygous deletions and truncated mutations, which result in loss of BRG protein) are more likely to develop drug resistance, early tumor relapse, and poor prognosis than SMARCA4 wild-type patients (9, 10). This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.